| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Immunology |
Division of Pediatric Hematology/Oncology, Childrens Hospital of Michigan [J. W. T., M. L. S., Y. R.], Experimental and Clinical Therapeutics Program, Barbara Ann Karmanos Cancer Institute [J. W. T., X. H., Y. G. R. M. M., Y. R., L. H. M.], and Departments of Pediatrics [J. W. T., Y. R.], Pharmacology [L. H. M.], and Internal Medicine [J. A. D., R. M. M.], Wayne State University School of Medicine, Detroit, Michigan 48201
The significantly higher event-free survival rates of Down syndrome (DS) children with acute myeloid leukemia compared with non-DS children is linked to increased sensitivity of DS myeloblasts to 1-ß-D-arabinofuranosylcytosine (ara-C) and the enhanced metabolism of ara-C to ara-C triphosphate (J. W. Taub et al., Blood, 87: 33953403, 1996). The cystathionine-ß-synthase (CBS) gene (localized to chromosome 21q22.3) may have downstream effects on reduced folate and S-adenosylmethionine pathways; ara-C metabolism and folate pools are linked by the known synergistic effect of sequential methotrexate and ara-C therapy. We have shown that relative CBS transcripts were significantly higher in DS compared with non-DS myeloblasts, and CBS transcript levels correlated with in vitro ara-C sensitivity (J. W. Taub et al., Blood, 94: 13931400, 1999). A leukemia cell line model to study the relationship of the CBS gene and ara-C metabolism/sensitivity was developed by transfecting CBS-null CCRF-CEM cells with the CBS cDNA. CBS-transfected cells were a median 15-fold more sensitive in vitro to ara-C compared with wild-type cells and generated 8.5-fold higher [3H]ara-C triphosphate levels after in vitro incubation with [3H]ara-C. Severe combined immunodeficient mice implanted with CBS-transfected CEM cells demonstrated greater responsiveness to therapy, reflected in significantly prolonged survivals after ara-C administration compared with mice implanted with wild-type cells and treated with the same dosage schedule. The transfected cells also demonstrated increased in vitro and in vivo sensitivity to gemcitabine. Deoxycytidine kinase (dCK) activity was approximately 22-fold higher in transfected CEM cells compared with wild-type cells. However, levels of dCK transcripts on Northern blots and protein levels on Western blots were nearly identical between CBS-transfected and wild-type cells. Collectively, these results suggest a posttranscriptional regulation of dCK in CBS-overexpressing cells that contributes to increased ara-C phosphorylation and drug activity. Further elucidating the mechanisms of increased sensitivity of DS cells to ara-C related to the CBS gene may lead to the application of these novel approaches to acute myeloid leukemia therapy for non-DS patients.
This article has been cited by other articles:
![]() |
K. Kudo, S. Kojima, K. Tabuchi, H. Yabe, A. Tawa, M. Imaizumi, R. Hanada, K. Hamamoto, R. Kobayashi, A. Morimoto, et al. Prospective Study of a Pirarubicin, Intermediate-Dose Cytarabine, and Etoposide Regimen in Children With Down Syndrome and Acute Myeloid Leukemia: The Japanese Childhood AML Cooperative Study Group J. Clin. Oncol., December 1, 2007; 25(34): 5442 - 5447. [Abstract] [Full Text] [PDF] |
||||
![]() |
U. Sen, N. Tyagi, M. Kumar, K. S. Moshal, W. E. Rodriguez, and S. C. Tyagi Cystathionine- -synthase gene transfer and 3-deazaadenosine ameliorate inflammatory response in endothelial cells Am J Physiol Cell Physiol, December 1, 2007; 293(6): C1779 - C1787. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. V. Massey, A. Zipursky, M. N. Chang, J. J. Doyle, S. Nasim, J. W. Taub, Y. Ravindranath, G. Dahl, and H. J. Weinstein A prospective study of the natural history of transient leukemia (TL) in neonates with Down syndrome (DS): Children's Oncology Group (COG) study POG-9481 Blood, June 15, 2006; 107(12): 4606 - 4613. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ge, M. L. Stout, D. A. Tatman, T. L. Jensen, S. Buck, R. L. Thomas, Y. Ravindranath, L. H. Matherly, and J. W. Taub GATA1, Cytidine Deaminase, and the High Cure Rate of Down Syndrome Children With Acute Megakaryocytic Leukemia J Natl Cancer Inst, February 2, 2005; 97(3): 226 - 231. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ge, T. L. Jensen, M. L. Stout, R. M. Flatley, P. J. Grohar, Y. Ravindranath, L. H. Matherly, and J. W. Taub The Role of Cytidine Deaminase and GATA1 Mutations in the Increased Cytosine Arabinoside Sensitivity of Down Syndrome Myeloblasts and Leukemia Cell Lines Cancer Res., January 15, 2004; 64(2): 728 - 735. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. E. Hansel, A. Rahman, M. Hidalgo, P. J. Thuluvath, K. D. Lillemoe, R. Shulick, J.-L. Ku, J.-G. Park, K. Miyazaki, R. Ashfaq, et al. Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology Am. J. Pathol., July 1, 2003; 163(1): 217 - 229. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ge, T. L. Jensen, L. H. Matherly, and J. W. Taub Transcriptional regulation of the cystathionine-beta -synthase gene in Down syndrome and non-Down syndrome megakaryocytic leukemia cell lines Blood, February 15, 2003; 101(4): 1551 - 1557. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Zwaan, G. J. L. Kaspers, R. Pieters, K. Hahlen, G. E. Janka-Schaub, C. H. van Zantwijk, D. R. Huismans, E. de Vries, M. G. Rots, G. J. Peters, et al. Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome Blood, January 1, 2002; 99(1): 245 - 251. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Ge, L. H. Matherly, and J. W. Taub Transcriptional Regulation of Cell-specific Expression of the Human Cystathionine beta -Synthase Gene by Differential Binding of Sp1/Sp3 to the -1b Promoter J. Biol. Chem., November 16, 2001; 276(47): 43570 - 43579. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |